TY  - JOUR
A1  - Glaser, Kirsten
A1  - Gradzka-Luczewska, Anna
A1  - Szymankiewicz-Breborowicz, Marta
A1  - Kawczynska-Leda, Natalia
A1  - Henrich, Birgit
A1  - Waaga-Gasser, Ana Maria
A1  - Speer, Christian P.
T1  - Perinatal ureaplasma exposure is associated with increased risk of late onset sepsis and imbalanced inflammation in preterm infants and may add to lung injury
JF  - Frontiers in Cellular and Infection Microbiology
N2  - Background: Controversy remains concerning the impact of Ureaplasma on preterm neonatal morbidity.

Methods: Prospective single-center study in very low birth weight infants <30 weeks' gestation. Cord blood and initial nasopharyngeal swabs were screened for Ureaplasma parvum and U. urealyticum using culture technique and polymerase chain reaction. Neonatal outcomes were followed until death or discharge. Multi-analyte immunoassay provided cord blood levels of inflammatory markers. Using multivariate regression analyses, perinatal Ureaplasma exposure was evaluated as risk factor for the development of bronchopulmonary dysplasia (BPD), other neonatal morbidities until discharge and systemic inflammation at admission.

Results: 40/103 (39%) infants were positive for Ureaplasma in one or both specimens, with U. parvum being the predominant species. While exposure to Ureaplasma alone was not associated with BPD, we found an increased risk of BPD in Ureaplasma-positive infants ventilated ≥5 days (OR 1.64; 95% CI 0.12–22.98; p = 0.009). Presence of Ureaplasma was associated with a 7-fold risk of late onset sepsis (LOS) (95% CI 1.80–27.39; p = 0.014). Moreover, Ureaplasma-positive infants had higher I/T ratios (b 0.39; 95% CI 0.08–0.71; p = 0.014), increased levels of interleukin (IL)-17 (b 0.16; 95% CI 0.02–0.30; p = 0.025) and matrix metalloproteinase 8 (b 0.77; 95% CI 0.10–1.44; p = 0.020), decreased levels of IL-10 (b −0.77; 95% CI −1.58 to −0.01; p = 0.043) and increased ratios of Tumor necrosis factor-α, IL-8, and IL-17 to anti-inflammatory IL-10 (p = 0.003, p = 0.012, p < 0.001).

Conclusions: Positive Ureaplasma screening was not associated with BPD. However, exposure contributed to BPD in infants ventilated ≥5 days and conferred an increased risk of LOS and imbalanced inflammatory cytokine responses.
KW  - Ureaplasma parvum
KW  - Ureaplasma urealyticum
KW  - preterm infants
KW  - VLBW
KW  - bronchopulmonary dysplasia
KW  - late onset sepsis
KW  - neonatal outcome
KW  - inflammation
Y1  - 2019
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-201270
VL  - 9
IS  - 68
ER  - 
TY  - JOUR
A1  - Kirsten, Natalia
A1  - Ohm, Frenz
A1  - Gehrdau, Kathrin
A1  - Girbig, Gefion
A1  - Stephan, Brigitte
A1  - Ben-Anaya, Nesrine
A1  - Pinter, Andreas
A1  - Bechara, Falk G.
A1  - Presser, Dagmar
A1  - Zouboulis, Christos C.
A1  - Augustin, Matthias
T1  - Switching from adalimumab originator to biosimilar in patients with hidradenitis suppurativa results in losses of response — data from the German HS registry HSBest
JF  - Life
N2  - Since 2021, adalimumab biosimilar ABP 501 can be used alternatively to adalimumab originator (ADAO) in the treatment of hidradenitis suppurativa (HS). Effectiveness and safety data remain scarce. We investigated the impact of switching from ADAO to ABP 501 on disease severity and the occurrence of adverse events (AEs) in patients with HS. We analyzed clinical data on patients enrolled in the German HSBest registry. Evaluation outcomes were assessed at three time points (baseline of originator (t0), prior to switching to biosimilar (t1) and 12 to 14 weeks after switching (t2)) and included patient-reported AEs and disease severity using the International Hidradenitis Suppurativa Severity Score System (IHS4) score. In total, 94 patients were switched from ADAO to ABP 501. Overall, 33.3% (n = 31/94) of the patients developed AEs and/or loss of response (LoR) within 12 to 14 weeks after switching. Of these, 61.3% (n = 19/31) experienced LoR but no AEs, 22.6% (n = 7/31) LoR combined with AEs and 16.1% (n = 5/31) AEs only. Our study showed that switching HS patients from ADAO to ABP 501 does significantly affect treatment effectiveness. Switching patients who are on remission maintenance therapy should be viewed critically.
KW  - hidradenitis suppurativa
KW  - biologics
KW  - TNF alpha
KW  - adverse drug reaction
KW  - biosimilar
KW  - drug effectiveness
KW  - switching
KW  - adalimumab
KW  - registry
Y1  - 2022
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288213
SN  - 2075-1729
VL  - 12
IS  - 10
ER  -